DOCS vs VEEV Stock Comparison: AI Score, Valuation, Performance and Upside
Doximity monetizes a physician-facing professional network primarily through pharmaceutical advertising with a high-margin, asset-light model, while Veeva Systems is the entrenched software-of-record for life sciences companies managing CRM, regulatory, and clinical operations. Both are dominant, high-margin healthcare software franchises, but they serve different ends of the pharmaceutical value chain — physicians versus the drug makers themselves.
Use this DOCS vs VEEV comparison to evaluate two dominant, high-margin healthcare software franchises serving different customers. Doximity's network effect is built around physician engagement and pharma advertising dollars, while Veeva's moat is built around mission-critical software embedded in life sciences companies' regulatory and commercial operations.
VEEV holds the edge across 4 of 5 key metrics in this comparison. VEEV has delivered stronger 1-year price return (+8.93% vs -53.71%), though DOCS has the better forward P/E setup (19.59x vs 27.41x for VEEV). VEEV leads on both revenue growth (17.60%) and operating margin (29.64%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for VEEV (+4.76%) than for DOCS (-2.73%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a dominant, high-margin physician network funded by pharmaceutical advertising
- Prefer an asset-light platform with strong free cash flow conversion
- Believe physician engagement and telehealth workflow tools remain durable long-term
- Are comfortable with revenue concentration in pharmaceutical advertising budgets
- Want exposure to the software-of-record for the life sciences industry's CRM and regulatory operations
- Value high switching costs and long-term customer retention within a mission-critical software category
- Prefer a consistently profitable, high-margin SaaS business model
- Are comfortable with growth tied to pharmaceutical and biotech industry spending cycles
| Metric | DOCS | VEEV |
|---|---|---|
| AI scorei | 24.3 | 56.5 |
| AI ranki | #3195 | #230 |
| Latest closei | $31.50 | $313.03 |
| 1M returni | +22.05% | +17.41% |
| 3M returni | +41.83% | +58.60% |
| 6M returni | +29.90% | +86.67% |
| 1Y returni | -53.71% | +8.93% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | DOCS | VEEV |
|---|---|---|
| 1Y ago | $4.68K (-53.2%) started 2025-10-16 | $10.69K (+6.9%) started 2025-10-16 |
| 5Y ago | $4.46K (-55.4%) started 2021-10-18 | $10.08K (+0.8%) started 2021-10-18 |
| 10Y ago | $5.94K (-40.6%) started 2021-06-24 | $82.44K (+724.4%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | DOCS | VEEV |
|---|---|---|
| Market capi | $5.44B | $45.45B |
| Trailing P/Ei | 34.66 | 46.10 |
| Forward P/Ei | 19.59 | 27.41 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 7.26 | 11.02 |
| Analyst targeti | $29.67 | $294.07 |
| Target upsidei | -2.73% | +4.76% |
| Metric | DOCS | VEEV |
|---|---|---|
| Revenue growthi | 7.30% | 17.60% |
| Earnings growthi | -51.90% | 39.50% |
| EPS growthi | -51.90% | +39.50% |
| FCF margini | +36.56% | +36.37% |
| Operating margini | 21.54% | 29.64% |
| Profit margini | 25.48% | 29.34% |
| ROIC proxyi | 17.21% | 14.42% |
| Return on equityi | 17.21% | 14.42% |
| Dividend yieldi | 0.00% | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 1.22 | 0.92 |
| Debt/equityi | 1.06 | 2.04 |
| Current ratioi | 6.08 | 5.46 |
| Quick ratioi | 5.80 | 5.36 |
Over the past year, DOCS and VEEV have moved moderately in the same direction (correlation of 0.40), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | DOCS | VEEV |
|---|---|---|---|
| 1Y | Growthi | -53.22% | +6.93% |
| CAGRi | -53.28% | +6.95% | |
| Volatilityi | 64.04% | 43.09% | |
| Sharpe ratioi | -0.94 | 0.26 | |
| Sortino ratioi | -1.31 | 0.41 | |
| Max drawdowni | 73.71% | 49.37% | |
| Current drawdowni | 54.01% | 0.00% | |
| Avg drawdowni | 53.68% | 27.64% | |
| Ulcer Indexi | 56.98% | 31.69% | |
| Max daily dropi | 23.00% | 9.77% | |
| Max wkly dropi | 30.81% | 16.81% | |
| 5Y | Growthi | -55.36% | +0.82% |
| CAGRi | -14.92% | +0.16% | |
| Volatilityi | 65.70% | 39.56% | |
| Sharpe ratioi | -0.00 | 0.09 | |
| Sortino ratioi | -0.00 | 0.13 | |
| Max drawdowni | 78.34% | 53.54% | |
| Current drawdowni | 62.11% | 3.76% | |
| Avg drawdowni | 50.19% | 34.46% | |
| Ulcer Indexi | 53.52% | 36.57% | |
| Max daily dropi | 23.00% | 16.24% | |
| Max wkly dropi | 32.63% | 21.64% | |
| 10Y | Growthi | -40.57% | +724.41% |
| CAGRi | -9.33% | +23.50% | |
| Volatilityi | 69.08% | 38.89% | |
| Sharpe ratioi | 0.12 | 0.62 | |
| Sortino ratioi | 0.20 | 0.93 | |
| Max drawdowni | 82.35% | 55.69% | |
| Current drawdowni | 69.12% | 8.20% | |
| Avg drawdowni | 58.41% | 22.72% | |
| Ulcer Indexi | 61.38% | 28.69% | |
| Max daily dropi | 23.00% | 16.24% | |
| Max wkly dropi | 32.63% | 21.64% |
| Category | DOCS | VEEV |
|---|---|---|
| Company | Doximity, Inc. | Veeva Systems Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Health Information Services | Health Information Services |
| Core business | Digital platform for U.S. physicians and healthcare professionals offering networking, telehealth workflow tools, and information resources, monetized primarily through subscriptions and advertising sold to pharmaceutical and health system clients. | Provider of cloud-based software for the life sciences industry, including customer relationship management (Veeva CRM) and content/quality management (Veeva Vault), used by pharmaceutical and biotech companies to manage regulatory, clinical, and commercial operations. |
| Investor focus | Subscription and advertising revenue growth, physician user engagement and network effects, and high incremental margins as the ad-supported model scales. | Subscription revenue growth, customer retention and expansion within the life sciences vertical, profitability and free cash flow margins, and progress of newer product lines beyond core CRM. |
- Dominant network effect among U.S. physicians, with a large majority of doctors registered on the platform
- High-margin, asset-light business model funded largely by pharmaceutical advertising and health system subscriptions
- Sticky professional network that is difficult for new entrants to replicate given physician trust and adoption
- Dominant, entrenched position in life sciences CRM and content management software with high switching costs
- Consistently profitable, high-margin SaaS business model with strong free cash flow generation
- Long track record of successful product expansion within its core life sciences vertical
- Revenue concentration in pharmaceutical advertising budgets, which can be cyclical
- Growth deceleration risk as physician market penetration in the U.S. matures
- Regulatory or reimbursement changes affecting telehealth workflow tools used within the platform
- Growth deceleration risk as its core life sciences CRM market matures and penetration increases
- Customer concentration within the pharmaceutical and biotech industry ties growth to that sector's spending cycles
- Competitive risk from broader enterprise CRM and data platforms attempting to enter life sciences
Compare more than two at a time
This page is a fixed writeup on DOCS and VEEV. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside DOCS and VEEV, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.